Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.120 -0.110 (-4.93%)
Streaming Delayed Price Updated: 2:40 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,677
Open 2.280
Bid (Size) 2.100 (3,800)
Ask (Size) 2.140 (300)
Prev. Close 2.230
Today's Range 2.100 - 2.290
52wk Range 1.110 - 5.500
Shares Outstanding 20,187,904
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
Via Investor Brand Network
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
From Annovis Bio Inc.
Via GlobeNewswire

Performance

YTD
-41.9%
-41.9%
1 Month
-20.6%
-20.6%
3 Month
-38.7%
-38.7%
6 Month
+2.4%
+2.4%
1 Year
+41.3%
+41.3%

More News

Read More
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
From NeuroRPM Inc.
Via GlobeNewswire
News headline image
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives Positive DSMB Recommendation to Continue Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
Via Investor Brand Network
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on January 28, 2026
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
Via Investor Brand Network
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗
Via Stocktwits
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
Via Investor Brand Network
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients ↗
Via Benzinga

Frequently Asked Questions

Is Annovis Bio, Inc. Common Stock publicly traded?
Yes, Annovis Bio, Inc. Common Stock is publicly traded.
What exchange does Annovis Bio, Inc. Common Stock trade on?
Annovis Bio, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Annovis Bio, Inc. Common Stock?
The ticker symbol for Annovis Bio, Inc. Common Stock is ANVS on the New York Stock Exchange
What is the current price of Annovis Bio, Inc. Common Stock?
The current price of Annovis Bio, Inc. Common Stock is 2.120
When was Annovis Bio, Inc. Common Stock last traded?
The last trade of Annovis Bio, Inc. Common Stock was at 04/01/26 02:40 PM ET
What is the market capitalization of Annovis Bio, Inc. Common Stock?
The market capitalization of Annovis Bio, Inc. Common Stock is 42.80M
How many shares of Annovis Bio, Inc. Common Stock are outstanding?
Annovis Bio, Inc. Common Stock has 43M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.